Increasing Prescription Drug Competition Act

This bill prevents brand-name drug companies from using patents related to drug safety programs (REMS) to delay generic drug approvals. It ensures that generic drug makers' certifications about these safety program patents do not delay their applications' approval dates. The bill also limits legal claims against generic makers who use safety program elements, allowing only monetary damages for infringement - not injunctions. It does not change required safety programs or affect antitrust laws. The bill directly affects drug manufacturers seeking approvals under FDA regulations and generic drug applicants.